These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
748 related articles for article (PubMed ID: 28764603)
1. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Conte B; Poggio F; Del Mastro L Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Bui KT; Willson ML; Goel S; Beith J; Goodwin A Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074 [TBL] [Abstract][Full Text] [Related]
4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Goel S; Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328 [TBL] [Abstract][Full Text] [Related]
5. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173 [TBL] [Abstract][Full Text] [Related]
6. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834 [TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. Francis PA Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169 [TBL] [Abstract][Full Text] [Related]
9. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661 [TBL] [Abstract][Full Text] [Related]
10. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Michaud LB; Buzdar AU Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521 [TBL] [Abstract][Full Text] [Related]
11. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Chlebowski RT; Pan K; Col NF Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653 [TBL] [Abstract][Full Text] [Related]
12. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time? Montagna E; Cancello G; Colleoni M Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ; Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609 [TBL] [Abstract][Full Text] [Related]
14. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ; J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365 [TBL] [Abstract][Full Text] [Related]
15. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. Colleoni M; Munzone E Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891 [TBL] [Abstract][Full Text] [Related]
16. [Adjuvant endocrine therapy in breast cancer]. Huober J; Thürlimann B Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910 [TBL] [Abstract][Full Text] [Related]
17. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. Pritchard KI Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918 [TBL] [Abstract][Full Text] [Related]
18. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866 [TBL] [Abstract][Full Text] [Related]
19. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study. Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022 [TBL] [Abstract][Full Text] [Related]
20. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM; J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]